Sandra K. Kostyk

Sandra K. Kostyk

Auto-generated profile, based on publicly available information

Sandra K. Kostyk

Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH

Research Focus & Metrics

Academic Career Length

49Years (1978-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2011 in The Lancet Neurology
Verified
Journal Article
Closed access
PLPeter A LeWitt
Peter A LeWitt
ARAli R Rezai
Ali R Rezai
MLMaureen A Leehey
Maureen A Leehey
SOSteven G Ojemann
Steven G Ojemann
AFAlice W Flaherty
Alice W Flaherty
AFAndrew Feigin
Andrew Feigin

1 May 2014 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
MBM. Flint Beal
M. Flint Beal
DODavid Oakes
David Oakes
ISIra Shoulson
Ira Shoulson
CHClaire Henchcliffe
Claire Henchcliffe
WGWendy R. Galpern
Wendy R. Galpern
KBKaryn Boyar
Karyn Boyar
Parkinson disease (PD) is a progressive neurodegenerative disorder commonly resulting in the loss of motor function, in nonmotor symptoms, and in cognitive decline. It affects 4.1 to 4.6 million people worldwide, and its prevalence is predicted to more than double by 2030.1 Strong evidence has emerged that mitochondrial dysfunction and increased oxidative stress play a pivotal role in the pathogenesis of PD, providing a robust scientific rationale for testing potential “neuroprotectants” that target these processes.2-4 Coenzyme Q10 (CoQ10) is a key component of the electron transport chain responsible for mitochondrial adenosine triphosphate generation, leads to decreased free radical generation, and, in its reduced form, acts as a powerful antioxidant.5 Coenzyme Q10 levels and redox status have been shown to be altered in individuals with PD,6 and CoQ10 has neuroprotective effects in multiple in vitro and animal models of neuronal toxicity, including the MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) model of PD.7 Finally, CoQ10 has shown promising clinical benefits in small human studies of progressive supranuclear palsy, Huntington disease, and Friedreich ataxia.8-10

1 August 2017 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
SFSamuel Frank
Samuel Frank
DSDavid Stamler
David Stamler
EKElise Kayson
Elise Kayson
DCDaniel O. Claassen
Daniel O. Claassen
ACAmy Colcher
Amy Colcher
FIfor the Huntington Study Group/Alternatives for Reducing Chorea in Huntington Disease Investigators
for the Huntington Study Group/Alternatives for Reducing Chorea in Huntington Disease Investigators
Huntington disease (HD) is a hereditary, progressive, neurodegenerative disorder characterized by chorea and other motor symptoms, cognitive dysfunction, and psychiatric symptoms. Up to 90% of patients with HD have chorea that can interfere with daily function and may cause injury.1,2 Tetrabenazine was the first drug approved by the US Food and Drug Administration for chorea associated with HD.3 High peak plasma concentrations and large plasma fluctuations may contribute to the tolerability issues observed in some patients with tetrabenazine use.4 Deutetrabenazine, a novel molecule that contains 6 deuterium atoms in place of 6 hydrogen atoms in specific positions in the tetrabenazine molecule, was approved for treating chorea associated with HD in 2017.5 Clinical evaluation in the First-HD trial found that deutetrabenazine provides significant chorea and motor improvement while maintaining a favorable safety profile when compared with placebo.6 The efficacy and excellent safety profile were attributed to the unique pharmacokinetic profile of deutetrabenazine, which enables comparable systemic exposure at lower doses, lower peak concentrations, and reduced plasma fluctuations.5 The current open-label study evaluated the safety and explored the efficacy of an overnight conversion from tetrabenazine to deutetrabenazine therapy with subsequent optional dose adjustment in patients with HD receiving a stable tetrabenazine regimen for chorea.

1 October 2007 in Physical Therapy
Verified
Journal Article
Closed access
PDF file
DKDeb A Kegelmeyer
Deb A Kegelmeyer
AKAnne D Kloos
Anne D Kloos
KTKaren M Thomas
Karen M Thomas
SKSandra K Kostyk
Sandra K Kostyk
Background and Purpose: This study examined the interrater and intrarater reliability, concurrent validity, and criterion validity of the Tinetti Mobility Test (TMT) as a fall risk screening tool in individuals with Parkinson disease (PD).

1 November 1994 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
PDF file
LML. P. McQuillan
L. P. McQuillan
GLG. K. Leung
G. K. Leung
PMP. A. Marsden
P. A. Marsden
SKS. K. Kostyk
S. K. Kostyk
SKS. Kourembanas
S. Kourembanas
Normal blood vessel tone is maintained by a balance of vasoconstrictors and vasodilators produced by endothelial cells in the vasculature. Nitric oxide (NO) is a potent vasodilator that causes vascular smooth muscle cell relaxation by elevating intracellular guanosine 3',5'-cyclic monophosphate (cGMP) levels. The physiological mechanisms regulating NO production in the vasculature are not completely understood. We report here that production of this vasodilator by vascular endothelial cells can be significantly suppressed by hypoxia. Exposing human endothelial cells to low PO2 results in 40–60% reduction in the steady-state mRNA levels of endothelial constitutive NO synthase (eNOS), the major enzyme responsible for NO production in these cells. The lower levels of eNOS mRNA result from decreased transcription of the gene as well as reduced message stability. In endothelial-smooth muscle cell co-culture experiments, hypoxic endothelial cells stimulated significantly less cGMP production by smooth muscle cells than the corresponding normoxic controls. This inhibitory effect of hypoxia on NOS production by endothelial cells occurs after 24 h of hypoxia and persists for at least 48 h. These new findings suggest that hypoxia might cause changes in blood vessel tone through compound mechanisms: by increasing the production of endothelium-derived vasoconstrictors and, as shown here, by suppressing the production of vasodilators like NO.

1 December 1982 in Behavioural Brain Research
Verified
Journal Article
Closed access
SKSandra K. Kostyk
Sandra K. Kostyk
PGPaul Grobstein
Paul Grobstein